Hibiscus (roselle) Sabdariffa gossypiifolia (Mill.) M.M.Hanes & R.L.Barrett
Also called: Hibiscus sabdariffa L. (synonym), roselle, sour tea, karkadi, zobo, sobolo
Roselle is a tropical hibiscus whose fleshy red calyces are brewed as a sour tea or drink and used as food and flavoring. POWO now accepts the name Sabdariffa gossypiifolia (2025); the studies cited here use Hibiscus sabdariffa.
- Category
- Botanical
- Part used
- Dried calyces, as tea, beverage or extract
- Strongest evidence
- B Some positive trials
- Native range
- Native from West Tropical Africa to Sudan (POWO native range: Central African Republic, Chad, Congo, DR Congo, Gabon, Ghana, Nigeria, Sudan-South Sudan); introduced widely in the tropics
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2025 umbrella review with updated meta-analysis pooled 26 RCTs (1,797 participants) of Hibiscus sabdariffa tea or extract; trials of multicomponent supplements were excluded, and 4 trials combined the extract with dietary advice. [3]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BHeart and blood vessels3 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood pressure in adults with hypertension (Cochrane) | C | A 2021 Cochrane review found only one eligible placebo-controlled trial (60 people with type 2 diabetes, 8 weeks) and judged the evidence insufficient, of very low certainty, to determine an effect on blood pressure. [2] |
| Blood pressure, lipids and glucose (umbrella review) | B | Pooling 26 randomized trials (1,797 participants), a 2025 umbrella review found dose-dependent reductions in systolic and diastolic pressure versus placebo and other teas, plus lower total and LDL cholesterol and fasting glucose and higher HDL. [3] |
| Fasting glucose and lipids | B | A 2020 meta-analysis of randomized trials found fasting glucose 3.96 mg/dL and LDL 7.84 mg/dL lower than placebo, with no significant change in total cholesterol, HDL or triglycerides. [4] |
Main constituents: Anthocyanins (delphinidin-3-sambubioside and cyanidin-3-sambubioside), organic acids (hydroxycitric acid and hibiscus acid) and phenolic acids (especially protocatechuic acid) [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Roselle extract capsules (total dose of 5600 mg) compared with placebo for 8 weeks (the single trial in the Cochrane review). [2]
- A single 150 ml dose of extract providing 147.4 mg total anthocyanins (pharmacokinetic study). [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
No NIH LiverTox chapter on hibiscus was found. A 2025 overview of 26 trials reported a minor, clinically insignificant increase in AST without increased adverse events.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines4 listed
Chloroquine; Simvastatin; Acetaminophen (paracetamol); Diclofenac
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
Interactions
| With | What happens |
|---|---|
| Chloroquine | In healthy men, taking chloroquine with karkadi (a hibiscus drink) cut chloroquine AUC from 7.52 to 2.16 mg·h/L and significantly lowered its peak concentration. [6] |
| Simvastatin | In six volunteers, a hibiscus beverage lowered simvastatin exposure (AUC ratio 0.646) and peak concentration by 18.0%. [7] |
| Acetaminophen (paracetamol) | In six healthy men, a hibiscus drink before acetaminophen did not change absorption but increased its clearance by 11.69%. [8] |
| Diclofenac | In healthy volunteers, 3 days of a hibiscus beverage reduced the amount of diclofenac excreted in urine. [9] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
Regulatory status
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; manufacturers and distributors have initial responsibility for their safety. [11]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming hibiscus or roselle (Hibiscus sabdariffa) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No NIH LiverTox chapter on hibiscus was found. A 2025 overview of 26 trials reported a minor, clinically insignificant increase in AST without increased adverse events. [P5]
Interactions with medicines
- Chloroquine: Coadministration with karkadi (hibiscus drink) significantly reduced chloroquine AUC (7.52 to 2.16 mg·h/L) and Cmax in healthy men; a parallel reduction in antimalarial efficacy might be expected. [P6]
- Simvastatin: In a randomized crossover study in six volunteers, a hibiscus beverage increased simvastatin clearance by 44.6% and reduced Cmax by 18.0% (AUC ratio 0.646). [P7]
- Acetaminophen (paracetamol): A hibiscus (zobo) drink taken before 1 g acetaminophen did not change absorption but increased total clearance by 11.69% in six healthy men. [P8]
- Diclofenac: Three days of a hibiscus beverage (300 ml/day) reduced urinary excretion of diclofenac in healthy volunteers. [P9]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each dietary-ingredient component (21 CFR 111.75(a)(1)(i)) — Required by the US dietary supplement cGMP rule for any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P10]
- Heavy metals, especially arsenic (AAS or ICP) — In Ghanaian market calyces, arsenic was the dominant contributor to estimated risk, and adult arsenic lifetime cancer-risk estimates reached 2.07 × 10⁻⁴, above the USEPA upper bound of 10⁻⁴ under conservative assumptions, although mean metal levels were below Codex and EU limits. [P11]
- Anthocyanin profile (delphinidin- and cyanidin-3-sambubioside) — Reviewers note most clinical extracts were phytochemically poorly characterized and name these anthocyanins among likely active constituents. [P1]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- In 6 healthy volunteers given 150 ml of extract (147.4 mg total anthocyanins), only 0.018% of anthocyanins were excreted intact in urine within 7 hours; plasma peaks occurred at 1.5 hours and half-lives were 2.18–3.34 hours. [P12]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Da-Costa-Rocha I, et al. Hibiscus sabdariffa L. - a phytochemical and pharmacological review. Food Chem 2014 (PMID 25038696), 2014-12-15. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications, Agents classified by the IARC Monographs, Volumes 1–142 (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- Norouzzadeh M, et al. Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: An overview of reviews and updated dose-response meta-analysis. Complement Ther Med 2025 (PMID 39870328), 2025-05. pubmed.ncbi.nlm.nih.gov
- Mahmoud BM, et al. Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. J Antimicrob Chemother 1994 (PMID 8089046), 1994-05. pubmed.ncbi.nlm.nih.gov
- Showande SJ, et al. In vivo pharmacodynamic and pharmacokinetic interactions of Hibiscus sabdariffa calyces extracts with simvastatin. J Clin Pharm Ther 2017 (PMID 28925046), 2017-12. pubmed.ncbi.nlm.nih.gov
- Kolawole JA, Maduenyi A. Effect of zobo drink (Hibiscus sabdariffa water extract) on the pharmacokinetics of acetaminophen in human volunteers. Eur J Drug Metab Pharmacokinet 2004 (PMID 15151167), 2004-01. pubmed.ncbi.nlm.nih.gov
- Fakeye TO, et al. Effects of water extract of Hibiscus sabdariffa, Linn (Malvaceae) 'Roselle' on excretion of a diclofenac formulation. Phytother Res 2007 (PMID 17094172), 2007-01. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75 (Title 21 up to date as of 10/27/2026), 2026-10-27. ecfr.gov
- Amponsah AS, et al. Dietary exposure and health risk assessment of heavy metals in hibiscus sabdariffa calyces sold in Ghanaian markets. J Environ Sci Health B 2026 (PMID 42535466), 2026. pubmed.ncbi.nlm.nih.gov
- Frank T, et al. Pharmacokinetics of anthocyanidin-3-glycosides following consumption of Hibiscus sabdariffa L. extract. J Clin Pharmacol 2005 (PMID 15647413), 2005-02. pubmed.ncbi.nlm.nih.gov
Sources
- Da-Costa-Rocha I, et al. Hibiscus sabdariffa L. - a phytochemical and pharmacological review. Food Chem 2014 (PMID 25038696), 2014-12-15. pubmed.ncbi.nlm.nih.gov
- Pattanittum P, et al. Roselle for hypertension in adults. Cochrane Database Syst Rev 2021 (PMID 34837382), 2021-11-27. pubmed.ncbi.nlm.nih.gov
- Norouzzadeh M, et al. Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: An overview of reviews and updated dose-response meta-analysis. Complement Ther Med 2025 (PMID 39870328), 2025-05. pubmed.ncbi.nlm.nih.gov
- Bule M, et al. The antidiabetic and antilipidemic effects of Hibiscus sabdariffa: A systematic review and meta-analysis of randomized clinical trials. Food Res Int 2020 (PMID 32156406), 2020-04. pubmed.ncbi.nlm.nih.gov
- Frank T, et al. Pharmacokinetics of anthocyanidin-3-glycosides following consumption of Hibiscus sabdariffa L. extract. J Clin Pharmacol 2005 (PMID 15647413), 2005-02. pubmed.ncbi.nlm.nih.gov
- Mahmoud BM, et al. Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. J Antimicrob Chemother 1994 (PMID 8089046), 1994-05. pubmed.ncbi.nlm.nih.gov
- Showande SJ, et al. In vivo pharmacodynamic and pharmacokinetic interactions of Hibiscus sabdariffa calyces extracts with simvastatin. J Clin Pharm Ther 2017 (PMID 28925046), 2017-12. pubmed.ncbi.nlm.nih.gov
- Kolawole JA, Maduenyi A. Effect of zobo drink (Hibiscus sabdariffa water extract) on the pharmacokinetics of acetaminophen in human volunteers. Eur J Drug Metab Pharmacokinet 2004 (PMID 15151167), 2004-01. pubmed.ncbi.nlm.nih.gov
- Fakeye TO, et al. Effects of water extract of Hibiscus sabdariffa, Linn (Malvaceae) 'Roselle' on excretion of a diclofenac formulation. Phytother Res 2007 (PMID 17094172), 2007-01. pubmed.ncbi.nlm.nih.gov
- Amponsah AS, et al. Dietary exposure and health risk assessment of heavy metals in hibiscus sabdariffa calyces sold in Ghanaian markets. J Environ Sci Health B 2026 (PMID 42535466), 2026. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Sabdariffa gossypiifolia (Mill.) M.M.Hanes & R.L.Barrett, first published Austral. Syst. Bot. 38-SB24013: 50 (2025); lists Hibiscus sabdariffa L. (nom. cons.) as a heterotypic synonym (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.